Target intelligence / Profile preview

Herpes simplex virus glycoprotein C (gC)

Target
gC
Molecular classification
Viral envelope protein, Glycoprotein, Complement regulator, Adhesion molecule
01

Overview

Herpes simplex virus glycoprotein C (gC) is a multifunctional type I integral membrane protein located on the viral envelope of both HSV-1 and HSV-2. It serves as the primary attachment ligand for the virus, mediating initial binding to host cell surface heparan sulfate and chondroitin sulfate proteoglycans. Beyond its role in entry, gC is a critical immune evasion factor that functions as a receptor for the host complement component C3b, thereby inhibiting the alternative complement pathway and protecting the virus from complement-mediated neutralization. In addition to its direct roles, gC acts as a physical shield for other essential glycoproteins, such as gB and gD, protecting them from neutralizing antibodies. It also facilitates viral entry through low-pH endosomal pathways by modulating the conformational transitions of the fusion protein gB. Because of its diverse roles in attachment and immune evasion, gC is a prominent target in the development of next-generation subunit vaccines and monoclonal antibody therapies aimed at preventing or treating herpes simplex infections.

Other names
Envelope glycoprotein CgC-1gC-2UL44Glycoprotein F
02

Mechanism of action

Inhibition of viral attachment to cell surface glycosaminoglycans, blockade of complement evasion by preventing C3b binding, and neutralization of viral entry by interfering with gC-mediated conformational changes in the fusion protein gB.

03

Biological functions

Viral attachment to host cellInhibition of host complement activationShielding of viral glycoproteins from neutralizationRegulation of low-pH viral entryHeparan sulfate binding
04

Disease associations

Infection
05

Safety considerations

Viral escape mutants (gC is non-essential for in vitro replication)Serotype-specific differences between HSV-1 and HSV-2Potential for immune evasion through antigenic variation
06

Interacting drugs

Trivalent HSV vaccine (experimental)

2 more in the full profile.

07

Biomarkers

Anti-gC antibodiesHSV-1/2 DNA

Beyond the preview

Go deeper on Herpes simplex virus glycoprotein C (gC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpes simplex virus glycoprotein C (gC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call